Dr David Roblin, CMO of Creabilis said: "AD and associated pruritus have a significant impact on patients' and carers' quality of life. Although some older treatments exist, there is a significant need for new therapies that are safe for long term use. A new therapeutic agent like CT327 that specifically addresses pruritus, the cardinal symptom of the disease, would make a real difference to patients."
Technology Strategy Board Biomedical Catalyst Funding
Creabilis was one of the inaugural recipients of a Biomedical Catalyst Award from the UK's innovation agency, the Technology Strategy Board,which has been used to partly fund the Phase 2b study in AD together with funding from existing investors. Creabilis is grateful to the Technology Strategy Board for its support.
Creabilis is a late clinical stage European biotechnology company with a primary focus in chronic pruritus (itch), a debilitating symptom of many dermatological diseases with a negative impact on quality of life. Chronic pruritus is an area of significant unmet need, with no medicine currently approved for its treatment.
Creabilis has delivered positive Phase 2b results for CT327 in the treatment of pruritus in psoriasis patients. CT327 is a novel, first-in-class, topically delivered TrkA kinase inhibitor. CT327 was developed using Creabilis' proprietary Low Systemic Exposure (LSE) 'topical-by-design' technology. LSE creates molecules optimized for topical applications. Planning for Phase 3 with CT327 is underway, with a clear route to market and an estimated >$800m in peak annual sales.
Creabilis' pipeline also includes CT340, a potent narrow spectrum kinase inhibitor in development for the topical treatment of neuropathic pain, an area of significant unmet medical need. Like CT327, CT340 was developed using the Company's Low Systemic
Copyright©2012 PR Newswire.
All rights reserved